BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man?s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs. This report contains market size and forecasts of Benign Prostatic Hyperplasia (BPH) Drugs in global, including the following market information:
- Global Benign Prostatic Hyperplasia (BPH) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global Benign Prostatic Hyperplasia (BPH) Drugs Market Sales, 2018-2023, 2024-2029, (M Units)
Global top five Benign Prostatic Hyperplasia (BPH) Drugs companies in 2022 (%)
The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ 3425.9 million in 2022 and is projected to reach US$ 4258.9 million by 2029, at a CAGR of 3.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
We surveyed the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, by Type, 2022 (%)
- Alpha-Blocker
- Phosphodiesterase Type-5 Inhibitors
- Others
Global Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospitals
- Drugstores
- Others
Global Benign Prostatic Hyperplasia (BPH) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Benign Prostatic Hyperplasia (BPH) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Benign Prostatic Hyperplasia (BPH) Drugs revenues share in global market, 2022 (%)
- Key companies Benign Prostatic Hyperplasia (BPH) Drugs sales in global market, 2018-2023 (Estimated), (M Units)
- Key companies Benign Prostatic Hyperplasia (BPH) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Eli Lilly
- GlaxoSmithKline
- Astellas Pharma
- Sanofi
- Pfizer
- Abbott
- Allergan
- TEVA
- Mylan
- Novartis
- Merck
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Benign Prostatic Hyperplasia (BPH) Drugs, market overview.
- Chapter 2: Global Benign Prostatic Hyperplasia (BPH) Drugs market size in revenue and volume.
- Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Benign Prostatic Hyperplasia (BPH) Drugs capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
